Description
BPC-157 + TB-500 is a dual-peptide research preparation combining Body Protection Compound-157 (a 15-amino acid sequence derived from a gastric juice protective protein) with TB-500 (synthetic Thymosin Beta-4), two compounds with complementary and well-documented roles in tissue repair research.
Research Overview
BPC-157 has been studied across gastrointestinal, musculoskeletal, tendon, ligament, and neural models over 25+ years, with the majority of published work from Dr. Predrag Sikirić’s group and collaborators at Zagreb. Its proposed mechanisms include VEGF upregulation (angiogenesis), nitric oxide system modulation, and interaction with growth hormone receptor signaling. Studies have demonstrated cytoprotective effects across diverse injury models including bowel anastomosis, muscle crush, and ischemia-reperfusion, with both local and systemic administration showing activity in rodent models. TB-500 (Thymosin Beta-4) has been characterized primarily through its role in sequestering G-actin monomers, freeing them for cell migration and wound closure. Cardiac research has documented Tβ4’s ability to mobilize cardiac progenitor cells following ischemic injury, with a landmark Nature paper (2004) establishing ILK as a downstream mediator. Tendon, corneal, and skin injury models show TB-500’s promotion of neovascularization and epithelialization. Research teams combining these compounds have noted that BPC-157’s angiogenic effects and TB-500’s actin-mediated cell migration represent distinct, non-redundant repair mechanisms — a rationale that continues to motivate combinatorial research designs.
Key References
- Sikirić P et al. (2018). Brain-gut Axis and Pentadecapeptide BPC 157. Current Neuropharmacology.
- Bock-Marquette I et al. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature.
- Goldstein AL et al. (2012). Thymosin β4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy.
Reviews
There are no reviews yet.